Clinicians report cases of rare neurological disorder following COVID-19 vaccination

In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barré syndrome after individuals were vaccinated against COVID-19.

Both reports describe an unusual variant of Guillain-Barré syndrome characterized by prominent facial weakness. Seven cases were reported from a regional medical center in Kerala, India, where approximately 1.2 million people were vaccinated with the AstraZeneca COVID-19 vaccine.

Four cases were reported from Nottingham, England, in an area in which approximately 700,000 people received the same vaccine. All eleven cases were among people who had received that vaccine 10-22 days earlier.

The frequency of Guillain-Barré syndrome in these areas was estimated to be up to 10 times greater than expected.

"If the link is causal it could be due to a cross-reactive immune response to the SARS-CoV-2 spike protein and components of the peripheral immune system," wrote the authors of the report from England.

Source:
Journal reference:

Maramatton, B. V., et al. (2021) Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine. Annals of Neurology. doi.org/10.1002/ana.26143.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients